The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale-Reference-Cited by-同舟云学术

The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale

Published:2018-06 Issue: Volume:69 Page:21-27
ISSN:1551-7144
Container-title:Contemporary Clinical Trials
language:en
Short-container-title:Contemporary Clinical Trials

Author:

Socias M. Eugenia,Ahamad Keith,Le Foll Bernard,Lim Ron,Bruneau Julie,Fischer Benedikt,Wild T. Cameron,Wood Evan,Jutras-Aswad Didier

Funder

Canadian Institutes of Health Research

Canadian Research Initiative in Substance Misuse

CIHR

Michael Smith Foundation for Health Research

University of Toronto

Publisher

Elsevier BV

Subject

Pharmacology (medical),General Medicine

Reference54 articles.

1. Effective Canadian policy to reduce harms from prescription opioids: learning from past failures;Fischer;CMAJ,2016

2. An urgent call to increase access to evidence-based opioid agonist therapy for prescription opioid use disorders;Socias;CMAJ,2016

3. Non-medical prescription opioid use, prescription opioid-related harms and public health in Canada: an update 5 years later;Fischer;Can. J. Public Health,2014

4. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction;Kolodny;Annu. Rev. Public Health,2015

5. Adopting the 'cascade of care' framework: an opportunity to close the implementation gap in addiction care?;Socias;Addiction,2016

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Opioid agonist treatment outcomes among individuals with a history of nonfatal overdose: Findings from a pragmatic, pan‐Canadian, randomized control trial;The American Journal on Addictions;2024-08-10

2. Mediating effect of craving on the impact of buprenorphine/naloxone and methadone treatment on opioid use: Results from a randomized controlled trial;Addictive Behaviors;2024-07

3. Impact of baseline methamphetamine/amphetamine use on discontinuation of methadone and buprenorphine/naloxone among people with prescription‐type opioid use disorder in Canada;The American Journal on Addictions;2024-06-15

4. Persistence in the Methadone Maintenance Program and Its Relationship with the Medication Regimen Complexity Index in Opioid-Dependent Patients;Pharmaceuticals;2024-04-29

5. Sexually transmitted and blood‐borne infection risk reduction with methadone and buprenorphine/naloxone among people with prescription‐type opioid use disorder: Findings from a Canadian pragmatic randomized trial;HIV Medicine;2024-03-20